{"organizations": [], "uuid": "a9764601478fefae218c994fb98a455074818537", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-reneuron-group-says-initial-cancer/brief-reneuron-group-says-initial-cancer-clinical-trial-application-planned-for-2019-idUSFWN1R802I", "country": "US", "domain_rank": 408, "title": "BRIEF-Reneuron Group Says Initial Cancer Clinical Trial Application Planned For 2019", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.969, "site_type": "news", "published": "2018-03-26T14:37:00.000+03:00", "replies_count": 0, "uuid": "a9764601478fefae218c994fb98a455074818537"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-reneuron-group-says-initial-cancer/brief-reneuron-group-says-initial-cancer-clinical-trial-application-planned-for-2019-idUSFWN1R802I", "ord_in_thread": 0, "title": "BRIEF-Reneuron Group Says Initial Cancer Clinical Trial Application Planned For 2019", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reneuron group plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Reneuron Group Plc:\n* RENEURON GROUP PLC - PHASE I/II STUDY TO BE EXPANDED TO TARGET PATIENTS WITH LESS IMPAIRED VISION AHEAD OF FUTURE PHASE IIB STUDY\n* RENEURON GROUP PLC - TOP LINE PHASE I/II DATA NOW EXPECTED IN H1 2019\n* RENEURON GROUP PLC - INITIAL CLINICAL TRIAL APPLICATION PLANNED FOR 2019 IN CANCER\n* RENEURON GROUP PLC - EXPECT SHORT TERM READ-OUTS FROM ONGOING PHASE I/II CLINICAL TRIAL LATER THAN ORIGINALLY PLANNED, IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T14:37:00.000+03:00", "crawled": "2018-03-27T11:37:35.000+03:00", "highlightTitle": ""}